Can repaglinide be used in patients with severe renal failure (eGFR < 30 mL/min/1.73 m²) or on dialysis?

Repaglinide Can Be Used in Severe Renal Failure with Careful Dose Adjustment

Yes, repaglinide can be used in patients with severe renal failure (eGFR < 30 mL/min/1.73 m²) and even in dialysis patients, making it one of the few oral antidiabetic agents safe in this population. However, you must start at 0.5 mg and titrate carefully.

FDA-Approved Dosing in Severe Renal Impairment

The FDA label explicitly addresses this scenario 1:

• Mild to moderate renal dysfunction (CrCl 40-80 mL/min): No initial dose adjustment required
• Severe renal impairment (CrCl 20-40 mL/min): Start with 0.5 mg and titrate carefully
• CrCl < 20 mL/min or hemodialysis: Not formally studied, but the drug is not contraindicated

Critical point: Studies were not conducted in patients with creatinine clearance below 20 mL/min or requiring hemodialysis, but the FDA label does not prohibit use—it simply notes lack of formal study data 1.

Why Repaglinide Works in Renal Failure

Repaglinide is primarily metabolized hepatically and excreted via bile (non-renal route), making it fundamentally different from most oral antidiabetic agents 2, 3. This pharmacokinetic profile is the key reason it remains safe when kidney function deteriorates.

Pharmacokinetic Evidence

Research demonstrates 4:

• Subjects with severe renal impairment had higher AUC values but no significant changes in maximum concentration or time to peak
• Hemodialysis did NOT significantly affect repaglinide clearance
• The drug was safe and well tolerated across all degrees of renal impairment

Clinical Efficacy and Safety Data

A multinational study of 130 patients with varying degrees of renal impairment showed 5:

• Safety profile remained good across all levels of renal function
• Hypoglycemic episodes increased with worsening renal function during run-in on other medications, but NOT during repaglinide treatment (p=0.074)
• Metabolic control (HbA1c, fasting glucose) was maintained
• Final doses tended to be lower in severe/extreme renal impairment (p=0.032)

A more recent Japanese study in CKD stage 4 patients (mean eGFR 26.4 mL/min/1.73 m²) demonstrated 6:

• HbA1c dropped from 7.7% to 6.1% (p<0.001) over 12 weeks
• No hypoglycemic symptoms or severe hypoglycemia in patients completing the study
• Superior efficacy when switched from DPP-4 inhibitors

Position in Current Guidelines

The 2022 KDIGO guidelines do NOT specifically recommend repaglinide as a preferred agent 7, 8. The guidelines prioritize:

1. SGLT2 inhibitors (down to eGFR 20 mL/min/1.73 m²)
2. GLP-1 receptor agonists
3. Then other agents including DPP-4 inhibitors, insulin, sulfonylureas, TZDs, and alpha-glucosidase inhibitors

However, repaglinide fills a critical niche when:

• SGLT2i and GLP-1 RA are contraindicated, not tolerated, or insufficient
• DPP-4 inhibitors fail to achieve glycemic targets (as shown in 6)
• You need an oral agent in severe CKD/dialysis where most options are contraindicated

Practical Algorithm for Use

Starting repaglinide in severe renal failure:

1. Initial dose: 0.5 mg with each meal (typically 3 times daily)
2. Titration: Wait at least 1 week between dose increases to assess full response 1
3. Maximum dose: Typically lower than in normal renal function; clinical studies showed final doses were lower in severe impairment 5
4. Monitoring:
   • Check blood glucose frequently during titration
   • Longer intervals between adjustments needed due to prolonged serum concentrations
   • Monitor for hypoglycemia, though risk appears lower than with sulfonylureas

In dialysis patients:

• Can be used despite lack of formal studies 1
• Hemodialysis does not remove repaglinide 4
• Same starting dose (0.5 mg) with careful titration

Key Advantages Over Alternatives

• Sulfonylureas: High hypoglycemia risk in renal failure—avoid glyburide entirely 8
• Metformin: Contraindicated at eGFR < 30 mL/min/1.73 m² 7, 8
• DPP-4 inhibitors: Require dose reduction and may be insufficient for glycemic control 6
• Repaglinide: Minimal renal excretion, flexible dosing with meals, lower hypoglycemia risk than sulfonylureas

Critical Caveats

1. Hepatic impairment: Use cautiously if liver disease coexists; higher and more prolonged drug concentrations occur 1
2. Not first-line: Per KDIGO guidelines, optimize SGLT2i and GLP-1 RA first when possible 7, 8
3. Meal-dependent dosing: Must be taken with meals; skip dose if meal is skipped
4. Drug interactions: Be aware of CYP3A4 and CYP2C8 interactions

Bottom line: Repaglinide is one of the safest oral antidiabetic options in severe renal failure and dialysis, but start low (0.5 mg), go slow with titration, and monitor carefully for hypoglycemia.